Importantly, we demonstrate these mechanisms are amenable to targeted therapy as genetic and pharmacological inhibition of IL-12- and TNFα-signaling ameliorates the competitive advantage of TET2-mutant cells in the presence of JAK2V617F-mutant MPN. Here, TNF is linked to myeloproliferative disorder.